EOLS vs ABBV vs ACLX vs SKIN vs INMD

For growth investors, Evolus, Inc.

(EOLS) is the stronger pick with 11. 6% revenue growth year-over-year, versus -79. 4% for Arcellx, Inc. (ACLX). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate Evolus, Inc. (EOLS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, InMode Ltd.

(INMD) is the cheapest at 9. 7x versus AbbVie Inc. at 85. 5x. On forward P/E, InMode Ltd. is actually cheaper at 9. 6x.

Over the past 5 years, Arcellx, Inc.

(ACLX) delivered a total return of +584. 9%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: ACLX returned +584. 9% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcellx, Inc.

(ACLX) is the lower-risk stock at -0. 34β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately -690% more volatile than ACLX relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evolus, Inc.

(EOLS) is pulling ahead at 11. 6% versus -79. 4% for Arcellx, Inc. (ACLX). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -103. 5% for Arcellx, Inc.. Over a 3-year CAGR, EOLS leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus -1027. 3% for Arcellx, Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -1135. 6% for ACLX. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, InMode Ltd.

(INMD) trades at 9. 6x forward P/E versus 14. 3x for AbbVie Inc. — 4. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EOLS: 134. 7% to $15. 00.

In this comparison, ABBV (3.

2% yield) pays a dividend. EOLS, ACLX, SKIN, INMD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Arcellx, Inc.

(ACLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 34), +584. 9% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACLX: +584. 9%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EOLS (Healthcare) and ABBV (Healthcare) and ACLX (Healthcare) and SKIN (Consumer Defensive) and INMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EOLS is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock; ACLX is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; INMD is a small-cap deep-value stock. ABBV pays a dividend while EOLS, ACLX, SKIN, INMD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.